Prospective Analysis of Versatility and User Satisfaction with a Novel Single-Use Cystoscope with Working Channel.

Authors:
Lütfrenk T; Neisius A; Rausch S; Salem J; Kuru TH.

Journal:
Urol Int

Publication Year: 2023

DOI:
10.1159/000529488

PMCID:
PMC10871682

PMID:
37071983

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Urol Int

Abbreviation: Urol Int

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Urology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Complete Blood Count Markers and C-Reactive Protein as Predictors of Testicular Viability in the Ev…
Barkai E; Dekalo S; Yossepowitch O and 4 more (2023) - Transparency Score: 3/6
Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guérin to P…
Tachibana T; Ikeda M; Shimura S and 10 more (2023) - Transparency Score: 3/6
Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C and 28 more (2023) - Transparency Score: 3/6
Focal Therapy for Renal Cancer: Comparative Trends in the USA and Germany from 2006 to 2020 and Ana…
Flegar L; Thoduka SG; Mahnken AH and 7 more (2023) - Transparency Score: 3/6
Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies.
Banek S; Hoeh B; Cano Garcia C and 6 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Statement S.R.: consultant/speaker honoraria for Advanced Accelerator Applications Germany GmbH, MDxHealth, Astellas Pharma, Pfizer Oncology, Bayer Oncology, Merck Pharma, Desitin, Ambu A/S, BMS Pharma, Eisai Pharma, and MSD Sharp & Dohme GmbH; A.N.: consultant/speaker honoraria for MSD, Janssen, AstraZeneca, Ispen, Amgen, Roche, GlaxoSmithKline, and Boston Scientific. T.K. and J.S.: consultant/speaker honoraria for LISA Laser, OptiMed, Ambu A/S, Boston Scientific, Olympus, Meditate, Dr. Schwabe, and Omega Pharma. T.L. has no conflicts of interest to declare."

Evidence found in paper:

"This study was financially supported by Ambu GmbH, D-61231 Bad Nauheim. Germany."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025